267 related articles for article (PubMed ID: 21592394)
1. Effects of 1α,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells.
Wang WL; Chatterjee N; Chittur SV; Welsh J; Tenniswood MP
Mol Cancer; 2011 May; 10():58. PubMed ID: 21592394
[TBL] [Abstract][Full Text] [Related]
2. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays.
Krishnan AV; Shinghal R; Raghavachari N; Brooks JD; Peehl DM; Feldman D
Prostate; 2004 May; 59(3):243-51. PubMed ID: 15042599
[TBL] [Abstract][Full Text] [Related]
3. GADD45gamma: a new vitamin D-regulated gene that is antiproliferative in prostate cancer cells.
Flores O; Burnstein KL
Endocrinology; 2010 Oct; 151(10):4654-64. PubMed ID: 20739400
[TBL] [Abstract][Full Text] [Related]
4. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1999 Mar; 140(3):1205-12. PubMed ID: 10067845
[TBL] [Abstract][Full Text] [Related]
5. 1,25-Dihydroxyvitamin D3 modulates lipid metabolism in prostate cancer cells through miRNA mediated regulation of PPARA.
Wang WL; Welsh J; Tenniswood M
J Steroid Biochem Mol Biol; 2013 Jul; 136():247-51. PubMed ID: 23059473
[TBL] [Abstract][Full Text] [Related]
6. VDR regulation of microRNA differs across prostate cell models suggesting extremely flexible control of transcription.
Singh PK; Long MD; Battaglia S; Hu Q; Liu S; Sucheston-Campbell LE; Campbell MJ
Epigenetics; 2015; 10(1):40-9. PubMed ID: 25494645
[TBL] [Abstract][Full Text] [Related]
7. Activin A regulates microRNAs and gene expression in LNCaP cells.
Ottley EC; Nicholson HD; Gold EJ
Prostate; 2016 Aug; 76(11):951-63. PubMed ID: 27018851
[TBL] [Abstract][Full Text] [Related]
8. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
Zhao XY; Peehl DM; Navone NM; Feldman D
Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
[TBL] [Abstract][Full Text] [Related]
9. 1α,25-Dihydroxyvitamin D
Ben-Eltriki M; Deb S; Guns EST
J Steroid Biochem Mol Biol; 2021 May; 209():105828. PubMed ID: 33493594
[TBL] [Abstract][Full Text] [Related]
10. Tumor suppressor microRNAs, miR-100 and -125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue.
Giangreco AA; Vaishnav A; Wagner D; Finelli A; Fleshner N; Van der Kwast T; Vieth R; Nonn L
Cancer Prev Res (Phila); 2013 May; 6(5):483-94. PubMed ID: 23503652
[TBL] [Abstract][Full Text] [Related]
11. The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha,25-dihydroxyvitamin D3 and its nuclear receptor.
Dunlop TW; Väisänen S; Frank C; Molnár F; Sinkkonen L; Carlberg C
J Mol Biol; 2005 Jun; 349(2):248-60. PubMed ID: 15890193
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer.
Flanagan JN; Zheng S; Chiang KC; Kittaka A; Sakaki T; Nakabayashi S; Zhao X; Spanjaard RA; Persons KS; Mathieu JS; Holick MF; Chen TC
Anticancer Res; 2009 Sep; 29(9):3547-53. PubMed ID: 19667147
[TBL] [Abstract][Full Text] [Related]
13. 1α,25(OH)2D3 differentially regulates miRNA expression in human bladder cancer cells.
Ma Y; Hu Q; Luo W; Pratt RN; Glenn ST; Liu S; Trump DL; Johnson CS
J Steroid Biochem Mol Biol; 2015 Apr; 148():166-71. PubMed ID: 25263658
[TBL] [Abstract][Full Text] [Related]
14. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D and testosterone co-ordinately modulate intracellular zinc levels and energy metabolism in prostate cancer cells.
Zhang P; Schatz A; Adeyemi B; Kozminski D; Welsh J; Tenniswood M; Wang WW
J Steroid Biochem Mol Biol; 2019 May; 189():248-258. PubMed ID: 30664926
[TBL] [Abstract][Full Text] [Related]
16. CCAAT/enhancer-binding protein delta: a molecular target of 1,25-dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells.
Ikezoe T; Gery S; Yin D; O'Kelly J; Binderup L; Lemp N; Taguchi H; Koeffler HP
Cancer Res; 2005 Jun; 65(11):4762-8. PubMed ID: 15930295
[TBL] [Abstract][Full Text] [Related]
17. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
Campbell MJ; Gombart AF; Kwok SH; Park S; Koeffler HP
Oncogene; 2000 Oct; 19(44):5091-7. PubMed ID: 11042697
[TBL] [Abstract][Full Text] [Related]
18. microRNAs and DICER1 are regulated by 1,25-dihydroxyvitamin D in prostate stroma.
Dambal S; Giangreco AA; Acosta AM; Fairchild A; Richards Z; Deaton R; Wagner D; Vieth R; Gann PH; Kajdacsy-Balla A; Van der Kwast T; Nonn L
J Steroid Biochem Mol Biol; 2017 Mar; 167():192-202. PubMed ID: 28089917
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer cell type-specific involvement of the VDR and RXR in regulation of the human PTHrP gene via a negative VDRE.
Sepulveda VA; Weigel NL; Falzon M
Steroids; 2006 Feb; 71(2):102-15. PubMed ID: 16243370
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of fatty acid synthase expression by 1alpha,25-dihydroxyvitamin D3 in prostate cancer cells.
Qiao S; Pennanen P; Nazarova N; Lou YR; Tuohimaa P
J Steroid Biochem Mol Biol; 2003 May; 85(1):1-8. PubMed ID: 12798352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
